Guard Therapeutics International AB (publ) (GUARD.ST)
SEK 12.25
(2.94%)
SEK 12.25
(2.94%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 115.07 Million SEK | 1.27% |
| 2022 | 113.62 Million SEK | 39.79% |
| 2021 | 81.28 Million SEK | 101.81% |
| 2020 | 40.27 Million SEK | -9.05% |
| 2019 | 44.28 Million SEK | -48.54% |
| 2018 | 86.05 Million SEK | 27.52% |
| 2017 | 67.48 Million SEK | 23.99% |
| 2016 | 54.42 Million SEK | 81.45% |
| 2015 | 29.99 Million SEK | 77.46% |
| 2014 | 16.9 Million SEK | 32.13% |
| 2013 | 12.79 Million SEK | 36.98% |
| 2012 | 9.33 Million SEK | 145.18% |
| 2011 | 3.8 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 17.27 Million SEK | 11.0% |
| 2024 Q2 | 23.73 Million SEK | 37.13% |
| 2023 Q4 | 15.56 Million SEK | -36.34% |
| 2023 Q2 | 34.67 Million SEK | -14.62% |
| 2023 FY | 114.9 Million SEK | 1.12% |
| 2023 Q3 | 24.44 Million SEK | -29.5% |
| 2023 Q1 | 40.61 Million SEK | 5.51% |
| 2022 Q4 | 38.49 Million SEK | 12.81% |
| 2022 Q3 | 34.12 Million SEK | 56.12% |
| 2022 Q2 | 21.85 Million SEK | 14.17% |
| 2022 Q1 | 19.14 Million SEK | -12.77% |
| 2022 FY | 113.62 Million SEK | 39.79% |
| 2021 Q3 | 34.46 Million SEK | 197.06% |
| 2021 FY | 81.28 Million SEK | 101.81% |
| 2021 Q1 | 13.27 Million SEK | 34.22% |
| 2021 Q2 | 11.6 Million SEK | -12.59% |
| 2021 Q4 | 21.94 Million SEK | -36.31% |
| 2020 Q1 | 9.64 Million SEK | -20.51% |
| 2020 Q3 | 12.82 Million SEK | 47.14% |
| 2020 Q4 | 9.88 Million SEK | -22.9% |
| 2020 FY | 40.27 Million SEK | -9.05% |
| 2020 Q2 | 8.71 Million SEK | -9.62% |
| 2019 FY | 44.28 Million SEK | -48.54% |
| 2019 Q3 | 8.03 Million SEK | -27.16% |
| 2019 Q4 | 12.13 Million SEK | 51.03% |
| 2019 Q1 | 13.09 Million SEK | -67.34% |
| 2019 Q2 | 11.02 Million SEK | -15.75% |
| 2018 Q1 | 14.6 Million SEK | -2.71% |
| 2018 Q4 | 40.08 Million SEK | 141.59% |
| 2018 Q3 | 16.59 Million SEK | 12.36% |
| 2018 FY | 86.05 Million SEK | 27.52% |
| 2018 Q2 | 14.76 Million SEK | 1.09% |
| 2017 Q3 | 18.33 Million SEK | -0.57% |
| 2017 Q1 | 15.69 Million SEK | -27.58% |
| 2017 Q4 | 15.01 Million SEK | -18.1% |
| 2017 FY | 67.48 Million SEK | 23.99% |
| 2017 Q2 | 18.43 Million SEK | 17.51% |
| 2016 FY | 54.42 Million SEK | 81.45% |
| 2016 Q3 | 14.37 Million SEK | 22.17% |
| 2016 Q4 | 21.66 Million SEK | 50.7% |
| 2016 Q2 | 11.76 Million SEK | 78.1% |
| 2016 Q1 | 6.6 Million SEK | -33.77% |
| 2015 Q2 | 8.33 Million SEK | 47.58% |
| 2015 Q3 | 6.92 Million SEK | -16.9% |
| 2015 Q1 | 5.65 Million SEK | 42.43% |
| 2015 Q4 | 9.97 Million SEK | 43.99% |
| 2015 FY | 29.99 Million SEK | 77.46% |
| 2014 FY | 16.9 Million SEK | 32.13% |
| 2014 Q4 | 3.96 Million SEK | -20.47% |
| 2014 Q3 | 4.98 Million SEK | 24.95% |
| 2014 Q2 | 3.99 Million SEK | 0.99% |
| 2014 Q1 | 3.95 Million SEK | 30.98% |
| 2013 Q4 | 3.01 Million SEK | -16.26% |
| 2013 FY | 12.79 Million SEK | 36.98% |
| 2013 Q2 | 3.69 Million SEK | 49.25% |
| 2013 Q1 | 2.47 Million SEK | 28.17% |
| 2013 Q3 | 3.6 Million SEK | -2.44% |
| 2012 Q4 | 1.93 Million SEK | -24.86% |
| 2012 Q3 | 2.57 Million SEK | 8.48% |
| 2012 FY | 9.33 Million SEK | 145.18% |
| 2012 Q2 | 2.36 Million SEK | 0.0% |
| 2011 FY | 3.8 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 92.401% |
| AcouSort AB (publ) | 25.87 Million SEK | -344.709% |
| Active Biotech AB (publ) | 44.8 Million SEK | -156.808% |
| Alzinova AB (publ) | 36.39 Million SEK | -216.169% |
| Amniotics AB (publ) | 29.07 Million SEK | -295.821% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -685.32% |
| BioArctic AB (publ) | 89.62 Million SEK | -28.391% |
| Camurus AB (publ) | 1.05 Billion SEK | 89.141% |
| Cantargia AB (publ) | 290.01 Million SEK | 60.322% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -425.567% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -306.24% |
| Genovis AB (publ.) | 88.19 Million SEK | -30.473% |
| Mendus AB (publ) | 129.13 Million SEK | 10.891% |
| Kancera AB (publ) | 63.07 Million SEK | -82.433% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1985.034% |
| LIDDS AB (publ) | 27.75 Million SEK | -314.648% |
| Lipum AB (publ) | 37.3 Million SEK | -208.449% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1486.339% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 15.333% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -601.622% |
| NextCell Pharma AB | -576.01 Thousand SEK | 20077.292% |
| OncoZenge AB (publ) | 15.9 Million SEK | -623.502% |
| Saniona AB (publ) | 1.07 Million SEK | -10584.587% |
| Simris Alg AB (publ) | 38.64 Million SEK | -197.793% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 64.208% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 67.823% |
| Xintela AB (publ) | 57.31 Million SEK | -100.769% |
| Ziccum AB (publ) | 27.87 Million SEK | -312.774% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1483.283% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 36.681% |
| CombiGene AB (publ) | 44.14 Million SEK | -160.676% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 19.522% |
| Intervacc AB (publ) | 79.78 Million SEK | -44.229% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 62.528% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -169.922% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -550.755% |
| Corline Biomedical AB | 30.16 Million SEK | -281.441% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -98.296% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -38.36% |
| Aptahem AB (publ) | 10.01 Million SEK | -1049.242% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 14.567% |
| Fluicell AB (publ) | 28.61 Million SEK | -302.114% |
| Biovica International AB (publ) | 133.72 Million SEK | 13.946% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -481.47% |
| Abliva AB (publ) | 27.86 Million SEK | -312.951% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 40.531% |
| 2cureX AB (publ) | 36.51 Million SEK | -215.113% |
| I-Tech AB | 40.14 Million SEK | -186.622% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 86.611% |
| Cyxone AB (publ) | 28.21 Million SEK | -307.858% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -5.216% |
| Biosergen AB | 26.8 Million SEK | -329.233% |
| Nanologica AB (publ) | 69.88 Million SEK | -64.656% |
| SynAct Pharma AB | 224.49 Million SEK | 48.742% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -160.488% |
| BioInvent International AB (publ) | 441.4 Million SEK | 73.93% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -380.386% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 60.285% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1364.728% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -3.75% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -682.81% |